The Executing Global Clinical Trial’s Conference Presents Fresh Data on Regulatory Hurdles and Cost Comparisons Around the

NEW YORK--(BUSINESS WIRE)-- The Conference Forum announced their new event on Executing Global Clinical Trial Operations in Washington, D.C. on September 28-29. The purpose of the program is to ultimately help the industry reduce clinical development time and features industry speakers from Purdue, Astellas, Pfizer, Eli Lilly, Sucampo, Otsuka Pharmaceutical Development & Commercialization, BBK, Combinatorx, RPS, Penn Center for Bioethics, Cephalon, PhRMA, AON, AHRQ and more. The conference features fresh data on country comparisons with regards to costs, study start ups and barriers to equip the industry in making better strategic decisions in choosing what country for what trial at what phase.

The agenda will also feature sessions on decision-making around the economic and operational realities in conducting international trials and includes a round table luncheon where attendees have one-on-one time with experts on Europe, Eastern Europe, Latin America, China, Japan, Korea and India.

“Global clinical trials are an increasingly indispensable part of drug development. This conference identifies and describes best practices associated with the strategy and conduct of global trials,” Mitch Katz, Executive Director, Medical Research Operations, Purdue and Conference Co-Chair.

The event will be held at The Embassy Suites, Washington Convention Center in Washington D.C. on September 28-29, 2010. Please visit www.theconferenceforum.org for more information or call 646 350 2580.

If you would like more information about this topic or to schedule an interview with one of the speakers, please contact Valerie Bowling at 646 350 2580 or email at [email protected].



CONTACT:

The Conference Forum
Valerie Bowling, 646-350-2580
[email protected]

KEYWORDS:   United States  North America  District of Columbia  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Medical Devices  Pharmaceutical  FDA

MEDIA:

Logo
 Logo

Suggested Articles

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.